A phase 2 trial of a COVID-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet. https://t.co/okeEfxUuxe pic.twitter.com/Cci0KMZi8U
— China.org.cn (@chinaorgcn) July 21, 2020
Chinese phase 2 trial finds vax is safe & induces an immune response. The clinical trial of an Ad5 vectored #COVID19 vaccine candidate was conducted in China by CanSino. Details published in The Lancet https://t.co/qVWfQ8zeUD via @medical_xpress
— delthia ricks 🔬 (@DelthiaRicks) July 20, 2020